Table 1.
Baseline characteristics of the eight randomized controlled trials included in the meta-analysis
| Phase | Underlying malignancy | Treatment arm | Control arm | Patients enrolled | Age (years), median (range) | Median OS (months) | Median PFS (months) | Jadad score | |
|---|---|---|---|---|---|---|---|---|---|
| Oza et al20 | II | OC | Olaparib 200 mg twice daily plus PC | PC | 162 | 59.0 (27–28) | 33.8 | 12.2 | 3 |
| Kaye et al19 | II | OC | Olaparib 200 mg twice daily Olaparib 400 mg twice daily |
PLD PLD |
32 32 |
58.5 (45–77) 53.5 (35–76) |
NA NA |
6.5 8.8 |
3 |
| Bang et al17 | II | GC | Olaparib 100 mg twice daily plus paclitaxel | Placebo/paclitaxel | 124 | 63.0 (31–77) | 13.1 | 3.9 | 5 |
| Ledermann et al18 | II | OC | Olaparib 400 mg twice daily | Placebo | 265 | 58.0 (21–89) | 29.7 | 8.4 | 5 |
| Bang et al8 | III | GC | Olaparib 100 mg twice daily plus paclitaxel | Placebo plus paclitaxel | 525 | 58.0 (49–67) | 8.8 | 3.7 | 5 |
| Pujade-Lauraine et al7 | III | OC | Olaparib 300 mg twice daily | Placebo | 295 | 56.0 (51–63) | NA | 19.1 | 5 |
| Robson et al9 | III | BC | Olaparib 300 mg twice daily | Single-agent chemotherapy | 302 | 44.0 (22–76) | 19.3 | 7.0 | 5 |
| Woll et al21 | II | SCLC | Olaparib 300 mg twice daily Olaparib 200 mg three times daily |
Placebo Placebo |
220 | 64.0 (42–89) | 9.9 9.0 |
3.6 3.6 |
4 |
Abbreviations: OC, ovarian cancer; SCLC, small-cell lung cancer; BC, breast cancer; GC, gastric cancer; PLD, PEGylated liposomal doxorubicin; PC, paclitaxel–carboplatin; PFS, progression-free survival; OS, overall survival; NR, not reported.